Literature DB >> 22221819

Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice.

Q Shi1, E L Kuether, J A Schroeder, S A Fahs, R R Montgomery.   

Abstract

Intravenous infusion studies in humans suggest that both von Willebrand factor (VWF) and factor VIII (FVIII) remain intravascular in contrast to other coagulation proteins. We explored whether infusion of VWF and FVIII by either intraperitoneal (i.p.) or subcutaneous (s.c.) injection would result in efficient absorption of these large proteins into the vascular circulation. FVIII(null) or VWF(null) mice were infused with plasma-derived or recombinant VWF and/or FVIII by i.p., s.c., or intravenous (i.v.) injection. Both VWF and FVIII were absorbed into the blood circulation after i.p. injection with a peak between 2 and 4 h at levels similar to those observed in mice infused intravenously. In contrast, neither VWF nor FVIII was detected in the plasma following s.c. injection. Although i.v. injection achieved peak plasma levels quickly, both human VWF and FVIII rapidly decreased during the first 2 h following i.v. injection. Following both i.v. and i.p. infusion of VWF, the multimeric structure of circulating VWF was similar to that observed in the infusate. These results demonstrate that both VWF and FVIII can be efficiently absorbed into the blood circulation following i.p., but not s.c. injection, indicating that i.p. administration could be an alternative route for VWF or FVIII infusion.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22221819      PMCID: PMC3323668          DOI: 10.1111/j.1365-2516.2011.02735.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  41 in total

1.  Absorption of protein from the peritoneal cavity.

Authors:  F C COURTICE; A W STEINBECK
Journal:  J Physiol       Date:  1951-07       Impact factor: 5.182

2.  Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.

Authors:  Lingfei Xu; Timothy C Nichols; Rita Sarkar; Stephanie McCorquodale; Dwight A Bellinger; Katherine P Ponder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-18       Impact factor: 11.205

3.  Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII.

Authors:  B E Fischer; G Kramer; A Mitterer; L Grillberger; M Reiter; W Mundt; F Dorner; J Eibl
Journal:  Thromb Res       Date:  1996-10-01       Impact factor: 3.944

Review 4.  Treatment of von Willebrand disease.

Authors:  Francesco Rodeghiero; Giancarlo Castaman
Journal:  Semin Hematol       Date:  2005-01       Impact factor: 3.851

5.  Lack of desmopressin (DDAVP) response in men with hemophilia A following liver transplantation.

Authors:  P A Lamont; M V Ragni
Journal:  J Thromb Haemost       Date:  2005-10       Impact factor: 5.824

6.  Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process?

Authors:  S A Brown; A Eldridge; P W Collins; D J Bowen
Journal:  J Thromb Haemost       Date:  2003-08       Impact factor: 5.824

Review 7.  Haemophilias A and B.

Authors:  Paula H B Bolton-Maggs; K John Pasi
Journal:  Lancet       Date:  2003-05-24       Impact factor: 79.321

Review 8.  von Willebrand factor.

Authors:  Z M Ruggeri; J Ware
Journal:  FASEB J       Date:  1993-02-01       Impact factor: 5.191

9.  Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells.

Authors:  R J Kaufman; L C Wasley; M V Davies; R J Wise; D I Israel; A J Dorner
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

10.  Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.

Authors:  Emmanuel J Favaloro; John Lloyd; John Rowell; Ross Baker; Kevin Rickard; Geoff Kershaw; Alison Street; Kate Scarff; Giulio Barrese; Darryl Maher; Andrew J McLachlan
Journal:  Thromb Haemost       Date:  2007-06       Impact factor: 5.249

View more
  15 in total

1.  A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.

Authors:  Takehisa Kitazawa; Tomoyuki Igawa; Zenjiro Sampei; Atsushi Muto; Tetsuo Kojima; Tetsuhiro Soeda; Kazutaka Yoshihashi; Yukiko Okuyama-Nishida; Hiroyuki Saito; Hiroyuki Tsunoda; Tsukasa Suzuki; Hideki Adachi; Taro Miyazaki; Shinya Ishii; Mika Kamata-Sakurai; Takeo Iida; Aya Harada; Keiko Esaki; Miho Funaki; Chifumi Moriyama; Eriko Tanaka; Yasufumi Kikuchi; Tetsuya Wakabayashi; Manabu Wada; Masaaki Goto; Takeshi Toyoda; Atsunori Ueyama; Sachiyo Suzuki; Kenta Haraya; Tatsuhiko Tachibana; Yoshiki Kawabe; Midori Shima; Akira Yoshioka; Kunihiro Hattori
Journal:  Nat Med       Date:  2012-09-30       Impact factor: 53.440

Review 2.  Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies?

Authors:  Abdullah Al Shoyaib; Sabrina Rahman Archie; Vardan T Karamyan
Journal:  Pharm Res       Date:  2019-12-23       Impact factor: 4.200

3.  Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.

Authors:  Matthew P Kosloski; Dipak S Pisal; Donald E Mager; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2013-04-25       Impact factor: 3.534

Review 4.  Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.

Authors:  Takehisa Kitazawa; Midori Shima
Journal:  Int J Hematol       Date:  2018-10-22       Impact factor: 2.490

5.  Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice.

Authors:  Nadine Vollack-Hesse; Olga Oleshko; Sonja Werwitzke; Barbara Solecka-Witulska; Christoph Kannicht; Andreas Tiede
Journal:  Blood       Date:  2021-02-25       Impact factor: 22.113

6.  G protein-dependent basal and evoked endothelial cell vWF secretion.

Authors:  Luiza Rusu; Alexandra Andreeva; David J Visintine; Kyungho Kim; Stephen M Vogel; Aleksandra Stojanovic-Terpo; Olga Chernaya; Guoquan Liu; Farnaz R Bakhshi; Sandra L Haberichter; Hiroko Iwanari; Osamu Kusano-Arai; Nobuchika Suzuki; Takao Hamakubo; Tohru Kozasa; Jaehyung Cho; Xiaoping Du; Richard D Minshall
Journal:  Blood       Date:  2013-09-30       Impact factor: 22.113

7.  The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.

Authors:  Yingyu Chen; Jocelyn A Schroeder; Juan Chen; Xiaofeng Luo; Christina K Baumgartner; Robert R Montgomery; Jianda Hu; Qizhen Shi
Journal:  Blood       Date:  2015-12-14       Impact factor: 22.113

8.  Von Willebrand factor delays liver repair after acetaminophen-induced acute liver injury in mice.

Authors:  Dafna Groeneveld; Holly Cline-Fedewa; Kevin S Baker; Kurt J Williams; Robert A Roth; Karen Mittermeier; Ton Lisman; Joseph S Palumbo; James P Luyendyk
Journal:  J Hepatol       Date:  2019-10-10       Impact factor: 30.083

9.  Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity.

Authors:  Zenjiro Sampei; Tomoyuki Igawa; Tetsuhiro Soeda; Yukiko Okuyama-Nishida; Chifumi Moriyama; Tetsuya Wakabayashi; Eriko Tanaka; Atsushi Muto; Tetsuo Kojima; Takehisa Kitazawa; Kazutaka Yoshihashi; Aya Harada; Miho Funaki; Kenta Haraya; Tatsuhiko Tachibana; Sachiyo Suzuki; Keiko Esaki; Yoshiaki Nabuchi; Kunihiro Hattori
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

10.  Thromboelastometry assessment of hemostatic properties in various murine models with coagulopathy and the effect of factor VIII therapeutics.

Authors:  Jocelyn A Schroeder; Erin A Kuether; Juan Fang; Weiqing Jing; Hartmut Weiler; David A Wilcox; Robert R Montgomery; Qizhen Shi
Journal:  J Thromb Haemost       Date:  2021-07-23       Impact factor: 16.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.